PHARMACY

Diamyd partners with NIH diabetes group in type 1 vaccine trial

BY Drew Buono

STOCKHOLM, Sweden Diamyd Medical and the National Institute of Diabetes and Kidney Diseases have joined together to initiate a clinical trial with Diamyds’ GAD-alum diabetes vaccine. The clinical trial will involve 126 new onset type 1 diabetes patients. The NIDDK-sponsored consortium type 1 diabetes TrialNet will conduct the clinical study.

The trial will include extensive immunological studies to clarify the mechanism of action and to evaluate the correlation between the clinical and immunological outcomes of GAD-alum Diamyd treatment in recent onset type 1 diabetes patients. The detailed analysis may provide important information into the ability of Diamyd to protect islet cells from autoimmune attack as an instrument for maintaining insulin production. Additionally, the immunological data may prove beneficial for designing future diabetes prevention studies.

“We are extremely excited to be working with NIDDK and TrialNet on this new Diamyd clinical study,” stated Anders Essen-Moller, chief executive officer of Diamyd Medical. “TrialNet is uniquely positioned to conduct clinical studies and to evaluate the molecular and cellular mechanisms of potential diabetes therapies. The insights expected from this trial should prove very valuable for Diamyd, the scientific community and for diabetes patients.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

Gene Logic receives milestone payment from Pfizer for drug repositioning

BY Drew Buono

GAITHERSBURG, Md. Gene Logic has reached a collaboration milestone, triggered by the filing of a patent application for a new use of an existing Pfizer drug candidate to treat solid tumors. Gene Logic’s Drug Repositioning Division discovered the new use for the unapproved drug candidate.

Under its drug repositioning agreement with Pfizer, Gene Logic has been seeking new therapeutic applications for selected drug candidates that are no longer in active development. The terms of the agreement provide for payment by Pfizer to Gene Logic of success-based milestones per compound and royalties on the commercialization of drugs whose repositioning results from Gene Logic’s Drug Repositioning Program. Gene Logic will receive a small initial milestone payment as a result of the filing of the patent application.

“We are pleased to see our Drug Repositioning Program yielding potentially valuable intellectual property for Pfizer. Our goal is to apply our drug repositioning capabilities to complement our partners’ internal pipeline development efforts,” Charles L. Dimmler, III, Gene Logic’s chief executive officer and president, said. “By finding new indications for de-prioritized, clinical stage drug candidates, our partners have another route to build value in their pipeline. We consider the filing of this patent application by Pfizer to be a substantive validation that our systematic approach to drug repositioning is working effectively.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

MedCenter system features monthly, not weekly pill boxes

BY Drew Buono

CINCINNATI With more and more patients forgetting to take their medications daily, technology has been developed to help these patients remember to take their medications each day and on time. The newest product on the market is the MedCenter System, a reminder system that combines a monthly medication organizer with an alarm clock that verbally reminds users to take their pills.

Unlike most weekly pill boxes, the MedCenter system consists of 31 daily date-specific pill boxes with four compartments so that the users can organize pills by daily dose times. Each day, the user visually matches the day of the months’ box with the clock’s large LCD date. At each dosage time, the talking alarm clock will remind the user to take his medication.

Many national retailers are already stocking the new product, ($69.95), including Kroger pharmacies. In addition, it’s available online at www.medcentersytems.com or amazon.com. More product information is available online www.medcentersystems.com.

“As my parents begin to age and their medications increased in number, they needed reminders to make certain that they took them properly,” said the inventor Martin Cooper. “The MedCenter system gives my brothers and me peace of mind that Mom and Dad are taking their medication properly.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?